Clinical Trial Update: PROCLAIM: Effect of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart Failure [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (PROCLAIM) evaluating AC2592 delivered by continuous subcutaneous infusion in subjects with advanced congestive heart failure has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• AC2592

Snippet

Sponsor: AstraZeneca | Conditions: Congestive Heart Failure | Phase 2 | Status: COMPLETED